Omnia Health Solutions

What Omnia Health Solutions does

Omnia Health Solutions is a privately held U.S. care and data company founded in April 2025 and headquartered in Austin, Texas, focused on chronic disease management with an initial emphasis on obesity and GLP-1 therapies. Its flagship is the BEACON Study, a decentralized, IRB-approved (protocol OMN-1000) longitudinal study that tracks medication adherence, clinical response, and quality-of-life outcomes over months and years rather than weeks. The BEACON platform integrates electronic health record data via a patient-mediated model, patient-reported outcomes, and digital engagement metrics from partners such as the Mayo Clinic Diet digital platform, and is augmented by the BEACON Community, a private moderated peer-support platform hosted on Bettermode. AI-powered analytics and predictive modeling are positioned as a core technology layer for treatment optimization and patient subtyping.

The company serves three primary customer segments: pharmaceutical companies seeking real-world evidence on GLP-1 therapies, primary care physicians and specialists who prescribe GLP-1s, and patients using GLP-1 medications themselves. Its go-to-market is enterprise field sales to pharma for data and research services, supplemented by a distributed physician referral network (including 11 CoreLife Novant Health clinics in North Carolina) and CME-accredited education delivered through the Obesity Medicine Association. Healthcare providers and patients participate at no cost; pharma research and data services are described as recurring/subscription engagements, though pricing is not publicly disclosed.

Name

Omnia Health Solutions

Legal name

Omnia Health Solutions, LLC

Website

https://omniahealthsolutions.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Omnia Health Solutions is a U.S. care and data company running the BEACON Study, a decentralized IRB-approved longitudinal platform that captures real-world GLP-1 outcomes and serves pharmaceutical companies, primary care physicians, and patients on GLP-1 therapies.

Ownership category

akta.pro rank

Product category

Real-World Evidence Research

SIC

Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB)

akta.pro secondary industry

Chronic Condition Medication Programs (e.g., diabetes, hypertension) with Integrated Prescribing (HLALAIAH)

Keywords

• Real-world evidence research
• Longitudinal clinical studies
• GLP-1 outcomes data
• Obesity care analytics
• Patient engagement platform

Headquarters

HQ city

Austin

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

1. Pharma Research Services: Omnia provides pharmaceutical companies with real-world evidence, longitudinal data insights, and predictive modeling to optimize therapies and improve patient outcomes. Revenue derived from research collaborations and data services with pharma partners seeking visibility from prescription to impact.
2. Healthcare Provider Network: Free tools, training, and CME education provided to physicians at no cost; practices participate in research network generating insights for pharma and payers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Omnia Health Solutions operates a care and data network centered on the BEACON Study, an IRB-approved decentralized longitudinal study capturing real-world outcomes of GLP-1 therapies for obesity by integrating EHR data, patient-reported outcomes, and digital health app metrics from physicians and patients over months and years. The company monetizes this longitudinal dataset by providing pharmaceutical companies with real-world evidence, predictive modeling, and treatment-optimization insights, while equipping healthcare providers with free tools, CME education, and benchmarking, and offering patients free participation with complimentary Mayo Clinic Diet access.

Product overview

Omnia Health Solutions offers a unified care and data platform centered on the BEACON Study, a decentralized, IRB-approved longitudinal research initiative focused on GLP-1 therapies and obesity management. The core BEACON platform integrates electronic health record (EHR) data, patient-reported outcomes, and digital health metrics to track treatment adherence, clinical outcomes, and patient experiences over time. The ecosystem includes the BEACON Community (a private peer-support platform for GLP-1 patients and caregivers) and integrates complementary services such as the Mayo Clinic Diet digital platform and CME education through the Obesity Medicine Association. AI-powered analytics support predictive modeling and treatment pathway optimization.

Differentiator

Problem solved

Functional benefit

Brands

• BEACON: Omnia's flagship decentralized, longitudinal study focused on understanding life on GLP-1 medications. BEACON combines IRB-approved longitudinal research and patient engagement to generate ongoing insight into treatment persistence, quality of life, behavioral trends, and the evolving experience of GLP-1 care.
• BEACON Community

Products and services

• BEACON Study A decentralized, IRB-approved longitudinal study platform that combines real-world outcomes research and patient engagement to generate ongoing insight into GLP-1 treatment persistence, quality of life, behavioral trends, and the evolving experience of GLP-1 care for physicians, patients, and pharmaceutical partners.
• BEACON Community A private, moderated online community for individuals taking FDA-approved GLP-1 therapies (such as Semaglutide or Tirzepatide) and their caregivers to connect, learn from experts and peers, and share experiences, with moderation supported by qualified healthcare professionals.

Quantifiable outcome

• 89% of primary care physicians report that patients struggle to stick with treatment plans even when therapies are prescribed
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• CoreLife HealthcarecoreStrategic or Co-development Partner · 27 January 2026Research collaboration supporting the BEACON Study. 11 CoreLife Novant Health clinics in North Carolina actively refer eligible patients into BEACON Study. Omnia conducts CoreLife cohort sub-analysis to evaluate outcomes among patients receiving GLP-1 therapy within CoreLife's structured, multidisciplinary care model (nutritional therapy, physical activity, behavioral support) compared to broader study population. CoreLife serves 500,000+ patients annually. Findings intended for sharing through abstracts, presentations, and publications.
• Obesity Medicine Association (OMA)coreStrategic or Co-development Partner · 16 September 2025Partnership to offer CME-accredited education and tools to support physicians and enhance care. Omnia presented research at OMA Annual Conference 2025 focusing on PCP perspectives on obesity and need for long-term outcomes data.
• Mayo Clinic DietcoreStrategic or Co-development Partner · 29 April 2025Strategic collaboration integrating the Mayo Clinic Diet's evidence-based digital lifestyle modification program into Omnia's care model. Mayo Clinic Diet provides clinically grounded behavioral support including flexible meal plans, nutrition guidance, and behavior support. Patients receive free subscription to the Mayo Clinic Diet digital platform. Collaboration extends impact beyond prescription pad, empowering lifestyle changes while generating real-world insights.
• NYU Langone HealthminorOthers · 29 April 2025Dr. Holly F. Lofton, Director of NYU Langone's Medical Weight Management Program, serves as Omnia advisor and provides clinical guidance. Dr. F. Lofton stated that 'Omnia is taking obesity care beyond the prescription, ensuring that physicians and patients have the right tools for long-term success.'

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Verily: Alphabet-owned life sciences platform operating decentralized clinical research and real-world evidence programs. Directly comparable to Omnia's patient-mediated, longitudinal BEACON approach and to its ambition to monetize longitudinal RWE with pharma.
• Flatiron Health: Roche-owned real-world evidence company curating large-scale clinical and genomic datasets for pharma. Comparable RWE-for-pharma business model and customer base to Omnia's pharma data-services revenue stream.
• Tempus AI: AI-powered real-world data platform combining multi-modal clinical data and analytics for pharma R&D. Comparable technology stack (longitudinal RWD + AI predictive modeling) and pharma buyer overlap with Omnia.
• Science 37: Decentralized clinical trial operator (now part of Emmes) focused on patient-mediated, in-home research. Comparable business model to Omnia's decentralized longitudinal study model and shared buyer (pharma sponsors).
• Medable: Decentralized clinical trial technology platform providing eCOA/ePRO, eConsent, and patient-facing data collection tools used by pharma and CROs. Closely comparable to BEACON's patient-mediated, app-based data capture architecture.

Broad incumbents

• IQVIA: Largest clinical research and real-world evidence organization globally with deep pharma enterprise contracts. A broad incumbent competing for the same pharma RWE wallet that Omnia targets, but with a far wider portfolio.
• Veradigm: Real-world evidence and life sciences data business built on large-scale EHR data. Broad incumbent with overlapping pharma RWE offerings, though not specialized in decentralized, patient-mediated longitudinal studies like BEACON.

Emerging players

• Ro: Direct-to-patient telehealth platform with weight-loss programs including GLP-1 prescribing. Competes with Omnia in the GLP-1/obesity care space but via a prescribing + pharmacy model rather than a research-data model.
• Found Health: Obesity medicine platform offering comprehensive care including GLP-1 medications alongside lifestyle support. Comparable obesity/GLP-1 focus to Omnia but delivers direct care rather than research-grade longitudinal evidence.
• Hims & Hers Health: Direct-to-consumer telehealth platform that includes GLP-1 prescriptions and weight-loss offerings. Overlaps with Omnia on the GLP-1 patient engagement surface, though Omnia focuses on longitudinal evidence rather than dispensing.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/omnia-health-solutions
• Facebookfacebook.com/profile.php

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Omnia Health Solutions